j nos pog ny pharmacist phd consultant to who shanghai 01 march 2005 e mail pogany@axelero hu n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Workshop on Quality Assurance and GMP of multisource HIV /AIDS medicines PowerPoint Presentation
Download Presentation
Workshop on Quality Assurance and GMP of multisource HIV /AIDS medicines

Loading in 2 Seconds...

play fullscreen
1 / 56

Workshop on Quality Assurance and GMP of multisource HIV /AIDS medicines - PowerPoint PPT Presentation


  • 182 Views
  • Uploaded on

János Pogány, pharmacist, PhD, consultant to WHO Shanghai, 01 March 2005 E-mail: pogany@axelero.hu. Workshop on Quality Assurance and GMP of multisource HIV /AIDS medicines. Pharmaceutical Research and Development Quality by design. Abbreviations and Notes.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Workshop on Quality Assurance and GMP of multisource HIV /AIDS medicines' - Pat_Xavi


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
j nos pog ny pharmacist phd consultant to who shanghai 01 march 2005 e mail pogany@axelero hu
János Pogány, pharmacist, PhD,

consultant to WHO

Shanghai, 01 March 2005

E-mail: pogany@axelero.hu

Workshop on Quality Assurance and GMP of multisource HIV/AIDSmedicines

Pharmaceutical

Research and Development

Quality by design

Dr. Pogány - WHO, Shanghai

abbreviations and notes
Abbreviations and Notes

API Active pharmaceutical ingredient

FDC(s) fixed-dose combination(s)

FPP(s) Finished pharmaceutical product(s)

R+D Research and development

Text in green refers to WHO documents or requirements

Text in yellow indicates a quality assessment issue

Text in light blue highlights key words

Dr. Pogány - WHO, Shanghai

subjects for discussion
Subjects for Discussion
  • Desk research—Indinavir
  • Submission of pharmaceutical R+D data
  • Research (Laboratory scale)
    • API (specifications, stress stability testing, etc.)
    • FPP (
  • Development (Pilot scale)
  • Manufacture(Production scale)
  • Conclusions

Dr. Pogány - WHO, Shanghai

what can we learn from the european public assessment report s epar s

What can we learn from the European Public Assessment Report(s) [EPAR(s)]?

DESK RESEARCH INDINAVIR

indinavir
Indinavir

Dr. Pogány - WHO, Shanghai

indinavir chemistry
Indinavir - Chemistry
  • Indinavir is a chiral molecule with 5 stereogenic centers and is used as a single isomer, the 4-(R)-epimer.
  • The primary degradation pathway for indinavir sulfate for both solid state and solution isamide bond hydrolysis to form lactone and aminoindanol. The degradation is humidity and temperature dependent.
  • Indinavir is highly hygroscopic at relative humidities above 60%. Indinavir Sulfate monoethanolateconverts to hydratewith the loss of ethanol upon exposure to moist air.

Dr. Pogány - WHO, Shanghai

indinavir physicochemistry
Indinavir – Physicochemistry
  • It has two pKb values: 6.2 and 3.8
  • Aqueous solubilityis 100mg/ml at room temperaturebut the solubility decreases at higher pH.
  • Partition coefficient octanol/water (log P) is 2.7 at pH 7.

Dr. Pogány - WHO, Shanghai

indinavir biology
Indinavir - Biology
  • Early clinical studies revealed a more reproducibleabsorption when indinavir was administered as the sulfate salt compared with the free base.
  • The bioavailabilityof indinaviris good(approximately 60 %,peak plasma concentration is 0.8 ±0.3 hours), which facilitates pre-formulation and formulation research.
  • Toxico-pharmacological information suggests that indinavir pharmaceutical forms may be manufactured inmultiproduct plants.

Dr. Pogány - WHO, Shanghai

indinavir preformulation
Indinavir - Preformulation
  • In view of indinavir sulfate’s moisture and temperature sensitivity, poor flowability and relatively loose bulk density, a dry granulation formulation with acceptable compressibility and consistent fill volume during encapsulation was developed.
  • Anhydrous lactose was selected as a filler and binding aid because of its low moisture content, non hygroscopicity and good compactibility.
  • Magnesium stearate provides the lubrication required for machinability.

Dr. Pogány - WHO, Shanghai

quality of inactive ingredients
Quality of inactive ingredients
  • Both capsule manufacturers have provided assurance that gelatin used will be obtained only from BSE-free countries (BSE = bovine (animal) spongiform encephalopathy).
  • The same assurance could be required for magnesium stearate, or stearic acid and its derivatives in general.

Dr. Pogány - WHO, Shanghai

crixivan capsules
Crixivan™Capsules
  • Indinavir, as sulfate100mg200mg
  • Lactose, anhydrous37mg74mg
  • Magnesium stearate??
  • Indinavir, as sulfate 333mg400mg
  • Lactose, anhydrous124mg149mg
  • Magnesium stearate??

Dr. Pogány - WHO, Shanghai

indinavir packing materials
Indinavir – Packing Materials
  • CRIXIVAN™ 100 mg: hard capsules are supplied in HDPE bottles with a polypropylene cap and a foil induction cap.
  • CRIXIVAN ™ 400 mg: hard capsules are supplied in all-aluminium blisters.

Dr. Pogány - WHO, Shanghai

indinavir labeling
Indinavir – Labeling
  • HDPE bottles: keep the container tightly closed in order to protect from moisture. Do not remove the desiccant canister from the bottle.
  • Blister packs: store in the original package in order to protect from moisture.
  • Note that the storage temperature is not indicated.

Dr. Pogány - WHO, Shanghai

indinavir stability of capsules
Indinavir – Stability of Capsules
  • No degradation other than the lactone and the aminoindanol were observed in any of the stressed capsules. The aminoindanol is produced in equimolar amount to the lactone.

Shelf life

  • 24 months for CRIXIVAN™ capsules in blisters.
  • 36 months for CRIXIVAN™ capsules in HDPE bottles.

Dr. Pogány - WHO, Shanghai

indinavir scale up
Indinavir – Scale up
  • The formulation intended for market has remained unchanged throughout the development program.Studies showed that the quality of the finished product is not compromised by the scale-up in production.
  • Flowability and bulk density of granules are important/critical parameters for weight variation.

Dr. Pogány - WHO, Shanghai

indinavir scale up1
Indinavir – Scale up
  • The manufacturing process is carried out under GMP at controlled humidity of the air in the manufacturing areas associated with roller compaction, milling and encapsulating.
  • HVAC system should maintain a relative humidity of ≤33% at 25oC.
  • The result of the manufacturing process development is a stable product with low batch-to-batch variation with the finishedproduct specification.

Dr. Pogány - WHO, Shanghai

indinavir quality control
Indinavir – Quality control

The specifications of the FPP cover the

  • Appearance of the capsules,
  • Identity,
  • Assay of drug substance,
  • Dose uniformity,
  • Dissolution test,
  • Test on degradation product and
  • Moisture content.

Dr. Pogány - WHO, Shanghai

indinavir quality control1
Indinavir – Quality control

At release,

  • an assay limit of 95-105 %
  • lactone impurity is not more than 0.3%.
  • Batch analyses data for several pilot scale lots used inclinical, safety and stability studies are submitted and demonstrate a consistent quality of the product and compliance with the stated specifications.

Dr. Pogány - WHO, Shanghai

indinavir quality control2
Indinavir – Quality control

At the end of shelf life,

  • an assay limit of93-105 % and
  • lactone impurityis not more than1.5%.
  • The stability studies of the FPP show that the drug product is stable when stored in the original container, tightly closed and protected from humidity.
  • Submission offull time stability data on production batches of the finished product is part of the follow-up measures.

Dr. Pogány - WHO, Shanghai

indinavir literature
Indinavir – Literature

CPMP/589/96 —Committee for Proprietary Medicinal Products (CPMP) European Public Assessment Report (EPAR)— The European Agency for the Evaluation of Medicinal Products, 7 Westferry Circus, Canary Wharf, London E14 4HB, UK

Additional sources of information:

United States patentNo. 5,413,999

Literature search on chemistry of indinavir.

Dr. Pogány - WHO, Shanghai

3 2 pharmaceutical research and development

Guideline on Submission of Documentation for Prequalification of Multi-source (Generic)Finished Pharmaceutical Products (FPPs)Used in the Treatment of HIV/AIDS, Malaria and Tuberculosis

3.2 PHARMACEUTICAL RESEARCH and DEVELOPMENT

objective of pharmaceutical r d
Objective of Pharmaceutical R+D
  • The Pharmaceutical R+D section presents the knowledge gained through the application of scientific approaches, and risk management, to the development of a FPP and its manufacturing process. It is first submitted in the original marketing application and can be updated to support new knowledge gained over the lifecycle of a product.
  • The studies described here are distinguished from routine control tests conducted according to specifications.

Dr. Pogány - WHO, Shanghai

preformulation

PREFORMULATION

Laboratory scale R + D

physicochemical and physical properties of api
Physicochemical

hygroscopicity

solubility

water content

polymorphism

permeability

Physical

particle size

bulk density(g/100ml)

flowability

color, olor, taste

consistency

Physicochemical and physical properties of API

Dr. Pogány - WHO, Shanghai

equilibrium moisture content
At relative humidities (RHs) <100%, a solid API (that does not form crystalline compounds with water) will loose some bound and all its unbound water until it is in equilibrium with the surrounding atmosphere. The sum of both these moistures is the free moisture of the API (granules) at the specified RH.Equilibrium Moisture Content

Dr. Pogány - WHO, Shanghai

solubility of zidovudine at 25 o c
Solubility of Zidovudine at 25oC

Dr. Pogány - WHO, Shanghai

relationship between permeability coefficient and octanol water partition
1 Prednisolone

...

3 Dexamethazone

...

9 Dexamethazone-acetate

...

11 Progesterone

Relationship between Permeability Coefficient and Octanol-Water Partition

Dr. Pogány - WHO, Shanghai

norvir ritonavir epar cpmp 527 96
NORVIR (Ritonavir) EPAR/CPMP /527/96
  • No polymorphism observed at the time of first submission (only form I : hard capsules and oral solution registered)
  • Failure in dissolution during stability studies for hard capsules
  • Emergence of form II (contamination of form I)
  • Production of hard capsules discontinued
  • Development and registration of soft capsules

Dr. Pogány - WHO, Shanghai

particle size
Particle Size

When the solubility of an API is less than 0.1 mg/ml, the optimization of the particle size during preformulation may be critical to efficacy or pharmaceutical equivalence. Other researchers believe that particle size may be critical at a solubility of 1 mg/ml or less.

Dr. Pogány - WHO, Shanghai

effect of particle size on dissolution
Effect of Particle Size on Dissolution

Dr. Pogány - WHO, Shanghai

screening of compositions
Screening of Compositions
  • Compatibility of an API with the excipients and the APIs with each other in FDCs is studied in open system stress stability experiments, e.g., 60-80 oC, 100% RH.
  • Regulatory stability studies of the final composition are frequently initiated in the pharmaceutical R + D laboratory.

Dr. Pogány - WHO, Shanghai

triomune whopar
Triomune - WHOPAR

Experimental„studies showed chemical incompatibility for thelamivudine with stavudine and nevirapine with stavudine combination. Lamivudine withnevirapine showed no change indicating that they are compatible. Stavudine was foundincompatible with both the drugs, indicated by the brown colouration and increase in theimpurities.

Therefore it was decided to separate stavudine from the other two drugs. Hence theformulation was proposed to be bilayered tablet formulation, where stavudine is in one layerand lamivudine + nevirapine in other layer. Thus contact of stavudine with the other two drugswas minimised.”

Dr. Pogány - WHO, Shanghai

dissolution test and profile
Dissolution Test and Profile
  • A (discriminating) dissolution test method should be developed for the final composition of the FPP.
  • Limits should be set for each API in fixed-dose FPPs.
  • The dissolution method should be incorporated into the stability and quality control programs.
  • Multipoint dissolution profiles of both the test and the reference FPPs should be compared.

Dr. Pogány - WHO, Shanghai

dissolution profile of viramune and generic nevirapine tablets on the indian market

F2

20

73

Dissolution Profile of Viramune and Generic Nevirapine Tablets on the Indian Market

Dr. Pogány - WHO, Shanghai

pivotal batches
Pivotal Batches

A tabulated summary of the compositions of the clinical, bioequivalence, stability and validationFPP batches together with documentation (batch number, batch size, manufacturing date and certificate of analysis at batch release) and a presentation of dissolution profilesmust be provided.

Results from comparative in vitro studies (e.g., dissolution) or comparative in vivo studies (e.g., bioequivalence) should be discussed when appropriate.

Dr. Pogány - WHO, Shanghai

excipients lactose l
Excipients – Lactose (L)

Different grade, different physical properties:

  • Angle of repose: 32- 47o (Specs.)
  • Bulk density: 0.34 – 0.80 g/cm3 (Specs.)
  • Bulk density (tapped): 0.41 – 0.95 g/cm3
  • Flowability (spray processed): 4.1 g/s (Specs.)
  • Hygroscopicity: L monohydrate is stable in air at room temperature. Anhydrous L may absorb humidity.
  • Moisture content: L monohydrate contains approx. 5% w/w water of crystallization

Dr. Pogány - WHO, Shanghai

excipients lactose l1
Excipients – Lactose (L)

Solubility in water

  • 1 in 4.63 at 25 oC
  • 1 in 3.14 at 40 oC
  • 1 in 2.04 at 50 oC
  • 1 in 1.68 at 60 oC
  • 1 in 1.07 at 80 oC

Particle size distribution: depends on grade.

Stability: may develop brown colouration (≥ 80% RH)

Incompatibility: APIs with a primary amine group (base catalysed), aminophylline and amphetamines.

Dr. Pogány - WHO, Shanghai

packaging materials
Packaging Materials
  • Moisture-impermeable containers: glass ampoules, vials closed with rubber stoppers and fixed with metal caps, aluminium/aluminium blisters, high density polyethylene (HDPE) or glass bottles fitted with metal metal or HDPE closures, etc.
  • Moisture-permeable containers: polyvinyl chloride (PVC) blisters, low density polyethylene (LDPE) bottles, HDPE bottles fitted with polypropylene closures.
  • Specifications of packaging materials should include thickness and permeability coefficient.

Dr. Pogány - WHO, Shanghai

justification of film coating
Justification of Film-coating
  • Mask bitter taste of the tablets
  • Reduce skin contact (risk of allergy)
  • Improve colour uniformity
  • Facilitate packaging

Dr. Pogány - WHO, Shanghai

results of api stress stability testing
Results of API Stress Stability Testing

Dr. Pogány - WHO, Shanghai

preformulation1
Preformulation
  • API is soluble in water, it can be easily granulated, compression results in good tablets with a rapid dissolution rate. There is no need for particle size reduction.
  • API is compatible with all excipients, including film-coating inactive ingredients.
  • Decomposition of API in UV and artificial daylight is not accelerated by the excipients.

Dr. Pogány - WHO, Shanghai

selection of tablet mass
Selection of Tablet Mass

Dr. Pogány - WHO, Shanghai

solvent selection for binder
Solvent Selection for Binder

Dr. Pogány - WHO, Shanghai

compression speed
Compression Speed

Dr. Pogány - WHO, Shanghai

film coating parameters
Film-coating Parameters

Dr. Pogány - WHO, Shanghai

film coating results
Film-coating Results

Dr. Pogány - WHO, Shanghai

choice of container
Choice of Container
  • Amber glass bottles with LDPE snap-fitting caps, and
  • Amber PVC/aluminium foil blister packs

General principle

Packaging should be selected to ensure the

quality of the FPP throughout its shelf life.

Dr. Pogány - WHO, Shanghai

pharmaceutical r d process includes transfer of technology to the production plant

Pharmaceutical R + D Process includes Transfer of Technology to the Production Plant

Production scale experiments with validation batches

validation protocol and report
Validation protocol and report
  • Data should be submitted in the application for prequalification demonstrating the validity of a given process.
  • Formal studies of production scale batches (normally not less than three consecutive batches) are required before the product is placed on the market.
  • Where validation data on production scale batches are not provided with the application, the applicant should submit the validation protocol.
  • Following completion of the programme, a validation report should be generated for examination by WHO.

Dr. Pogány - WHO, Shanghai

main points again
Main points again
  • Pharmaceutical R + D is an essential part of applications for Marketing Authorization.
  • Desk research gives valuable information.
  • Laboratory scale studiesshould identifycritical product quality attributes.
    • FDCs require particular tests.
    • Packing materials should also be selected through documented experiments.

Dr. Pogány - WHO, Shanghai

main points again1
Main points again
  • Pilot plant experiments should provide the basis for process optimisation, process validation and process control requirements.
  • Validation batches at production scale should establish the critical process parameters (e.g., granulation end point, drying temperature) that should regularly be monitored or controlled to guarantee batch-to-batch consistency of quality.

Dr. Pogány - WHO, Shanghai

thank you
THANK YOU

谢谢!

Dr. Pogány - WHO, Shanghai